STAT+: Pharmalittle: Data confirm benefits and risks of Lilly Alzheimer’s drug; Medicare aims to pay hospitals to stockpile essential drugs
Rise and shine, everyone, another busy day is on the way. We can tell because…
Category: STAT+
STAT+: Flagship, Pfizer team up in deal worth $7 billion
Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a…
.jpg)
STAT+: Startup Neumora takes a novel depression drug to Phase 3
Neumora, a privately held biotech company, is moving into the final phase of testing with…
STAT+: As digital health tech proliferates, a new institute aims to cut through hype
A new $50 million nonprofit initiative aims to independently evaluate health technologies’ impact on costs…
STAT+: Conservative group opposing PBM reform spends record number on lobbying
WASHINGTON — A conservative group advocating against changing how pharmacy middlemen operate spent more than…
STAT+: Medicare has a new plan to address drug shortages — but it could backfire
WASHINGTON — Medicare has a new proposal to pay hospitals more to stockpile essential drugs…
STAT+: Medicare to cover more brain scans for Alzheimer’s patients
WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can…
STAT+: Key House panel plots a new health care package — complicating the chamber’s agenda
WASHINGTON — It’s two weeks until Congress leaves town in August, and a prominent House panel…
STAT+: Colombian government explores compulsory licensing for an HIV drug
The latest clash over the cost of a prescription medicine is playing out in Colombia,…
STAT+: Electronic health record maker NextGen Healthcare to pay $31 million to resolve fraud claims
The health records company NextGen Healthcare will pay $31 million to resolve allegations that it…
STAT+: Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid…
STAT+: Detailed data confirm benefits — and risks — of Eli Lilly’s Alzheimer’s drug
The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed…
STAT+: Pharmalittle: Alzheimer’s diagnosis revamp embraces rating scale similar to cancer; FTC seeks info on Pfizer-Seagen deal
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: BridgeBio heart drug succeeds in pivotal study
A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition…
STAT+: Westlake Village, a West Coast VC firm, raises $450 million fund
Westlake Village BioPartners, a West Coast biotech venture capital firm founded five years ago by…
STAT+: Blue Cross Blue Shield plans in California evaded $170 million in taxes, whistleblower says
Two dominant Blue Cross Blue Shield companies in California intentionally underreported premiums of certain health…
STAT+: As fear rises over AI, Google and Epic fight stronger regulation of the technology in health care
Big businesses poised to profit from the advance of artificial intelligence in health care are…
STAT+: Argenx antibody drug significantly slows progression of nerve disorder that robs patients of muscle strength
Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression…
STAT+: Demand spikes in seniors, behavioral health care challenge UnitedHealth’s provider arm
UnitedHealth Group’s Optum subsidiary saw a lower operating margin in the second quarter due to…
STAT+: Eli Lilly to acquire Versanis in heated race for weight loss drugs
Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity…
STAT+: Pharmalittle: Key Senate panel has a plan for PBMs; Roivant eyes $7 billion sale of a stomach drug
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Three women sue cancer diagnostic firm Grail alleging harassment, retaliation
Three sales executives, all of them women, have filed suit against Grail, a cancer diagnostics…
Big Health acquires Limbix, maker of mental health app for depression in adolescents
Big Health, one of the leading companies producing apps to help treat mental health conditions,…
STAT+: With momentum on Alzheimer’s therapies, Europe sees delivery challenges ahead, too
LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at…
STAT+: Why hospitals are cutting ties with Moody’s rating agency
Not-for-profit hospitals have been cutting ties with Moody’s Investors Service in recent years, citing the…
STAT+: Medicare eyes cuts to doctors, raises to outpatient clinics in 2024
Physicians are in line to absorb more Medicare cuts next year, while hospital outpatient departments…
STAT+: House panel passes public health bills following contentious debate
WASHINGTON — The House Energy and Commerce health subcommittee on Thursday voted along party lines…
STAT+: Caribou posts encouraging durability results on its off-the-shelf CAR-T therapy
Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients…
STAT+: How a key Senate committee is planning to regulate pharmacy benefit managers
WASHINGTON — A key Senate health care panel has developed a plan to tackle reforms…
STAT+: HHS leader to vaccine makers: Set ‘reasonable’ prices for your next round of Covid-19 vaccines
Amid ongoing controversy over the cost of medicines, a key Biden administration official told Covid-19…
STAT+: Roche shortens delivery time for multiple sclerosis drug from hours to minutes in trial
For people living with multiple sclerosis, slowing or stopping this chronic and debilitating neurological disease…
STAT+: Pharmalittle: Congress is letting a drug shortages fix pass it by; FDA voucher program may lapse in October
Rise and shine, folks, another busy day is on the way. Already, there was a…
STAT+: Flagship recruits former BMS, Celgene R&D chief Rupert Vessey
After leaving his post as the head of research at Bristol Myers Squibb, Rupert Vessey…
There’s a bill well-suited for drug shortage reforms, but Congress isn’t interested
WASHINGTON — Congress is considering a must-pass pandemic preparedness bill that presents a good opportunity…
STAT+: More hospitals are billing patients as online messages surge
Health systems drowning in messages from patients are grasping for new ways to manage the…
STAT+: Pharmalittle: EU fines Illumina $475M for closing Grail deal; life-threatening lead poisoning antidote in short supply
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Europe issues maximum antitrust fine of $475 million to Illumina over Grail deal
LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to…
STAT+: How are insurers handling the Alzheimer’s drug Leqembi and related scans?
WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to…
STAT+: How to ‘break the logjam’? Economists pitch a plan to curb dire drug shortages
There are alarmingly frequent reports of shortages of vitally needed medicines. From tablets to treat…
STAT+: Pharmalittle: Eisai exec who helped lead Alzheimer’s drug development to retire; Express Scripts adds three Humira biosimilars to preferred formulary
Top of the morning to you, and a fine one it is. Birds are chirping…
STAT+: Eisai executive who helped lead development of Alzheimer’s drug to retire
Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global…
STAT+: How UnitedHealth’s acquisition of a popular Medicare Advantage algorithm sparked internal dissent over denied care
Frustration was boiling into open conflict within NaviHealth, a company that uses computer predictions to…
STAT+: NIH fellows, weighing a union, want a pay raise. Will that mean less money for grants?
Several thousand research fellows at the National Institutes of Health want to unionize, in large…
STAT+: Pharmalittle: European regulator probes suicidal risks of weight loss drugs; Pfizer reports shortages of penicillin for fighting syphilis
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Blue Cross Blue Shield insurers keep winning from Affordable Care Act’s risk program
A program that undergirds the Affordable Care Act’s health insurance marketplaces continues to bolster the…
STAT+: The new weight loss drugs are revolutionizing our understanding of desire. Food cravings could be just the beginning
One month it was pizza. Starting in the late afternoon, while he was teaching a…
STAT+: Medicare wants to send $9 billion to 340B hospitals — coupled with cuts
WASHINGTON — Medicare is planning to send $9 billion in lump sum payments to more…
STAT+: Home health providers sue Medicare over payment cuts, despite near record profits
The National Association of Home Care and Hospice sued the Biden administration to halt the…
STAT+: House panel expected to mark up pandemic-preparedness bill next week
WASHINGTON — A House subcommittee will next week mark up a package of public health…
STAT+: Pharmalittle: FDA grants full approval to Alzheimer’s drug; Sanders blocks NIH nominee over drug costs
And so, another working week will soon draw to a close. Not a moment too…